Journal Article

Polymorphisms at the glutathione <i>S</i>-transferase <i>GSTM1</i>, <i>GSTT1</i> and <i>GSTP1</i> loci: risk of ovarian cancer by histological subtype

Amanda B. Spurdle, Penelope M. Webb, David M. Purdie, Xiaoqing Chen, Adele Green and Georgia Chenevix-Trench

in Carcinogenesis

Volume 22, issue 1, pages 67-72
Published in print January 2001 | ISSN: 0143-3334
Published online January 2001 | e-ISSN: 1460-2180 | DOI: http://dx.doi.org/10.1093/carcin/22.1.67
Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics

GO

Show Summary Details

Preview

The phase II glutathione S-transferases (GSTs) GSTT1, GSTM1 and GSTP1 catalyse glutathione-mediated reduction of exogenous and endogenous electrophiles. These GSTs have broad and overlapping substrate specificities and it has been hypothesized that allelic variants associated with less effective detoxification of potential carcinogens may confer an increased susceptibility to cancer. To assess the role of GST gene variants in ovarian cancer development, we screened 285 epithelial ovarian cancer cases and 299 unaffected controls for the GSTT1 deletion (null) variant, the GSTM1 deletion (null) variant and the GSTP1 codon 104 A→G Ile→Val amino acid substitution variant. The frequencies of the GSTT1, GSTM1 and GSTP1 polymorphic variants did not vary with tumour behaviour (low malignant potential or invasive) or p53 immunohistochemical status. There was a suggestion that ovarian cancers of the endometrioid or clear cell histological subtype had a higher frequency of the GSTT1 and GSTM1 deletion genotype than other histological subgroups. The GSTT1, GSTM1 and GSTP1 genotype distributions did not differ significantly between unaffected controls and ovarian cancer cases (overall or invasive cancers only). However, the GSTM1 null genotype was associated with increased risk of endometrioid/clear cell invasive cancer [age-adjusted OR (95% CI) = 2.04 (1.01–4.09), P = 0.05], suggesting that deletion of GSTM1 may increase the risk of ovarian cancer of these histological subtypes specifically. This marginally significant finding will require verification by independent studies.

Keywords: CI, confidence interval; FAM, 6-carboxyfluorescein; GST, glutathione S-transferase; GSTM1, glutathione S-transferase μ1; GSTP1, glutathione S-transferase π1; GSTT1, glutathione S-transferase θ1; HWE, Hardy–Weinberg equilibrium; LMP, low malignant potential; OR, odds ratio; SDS, sequence detection system; TAMRA, 6-carboxy-N,N,N′,N′-tetramethylrhodamine; TET, 6-carboxy-4,7,2′,7'-tetrachlorofluoroscein.

Journal Article.  5304 words. 

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.